Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04310826 · ClinicalTrials.gov registry record · NA
Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy
A NA study of Ovarian Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT04310826: Active NA study of Ovarian Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT04310826 is a NA study of Ovarian Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 26 participants, below the 3,243-participant average among 35 other Ovarian Carcinoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04310826, a NA study of Ovarian Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how well a diet high in magnesium works in preventing low blood magnesium levels (hypomagnesemia) in patients with ovarian cancer receiving carboplatin chemotherapy. Hypomagnesemia is a common side effect of carboplatin-containing chemotherapy. A magnesium rich diet may increase the levels of magnesium in the blood and help prevent hypomagnesemia resulting from carboplatin chemotherapy.
Primary Outcome
Assessed by percentage of patients completing the dietary intervention. If a patient participated 60% or more of the weekly follow up by the end of the 6th cycle of treatment, she is considered retained. Descriptive statistics (e.g., frequencies, proportions, means, standard deviations \[SDs\], and ranges), along with 95% confidence intervals (CIs) for the means, will be computed.
Conditions Studied
Interventions
- OTHER Media Intervention
- DIETARY_SUPPLEMENT Dietary Intervention
- BEHAVIORAL Telephone-Based Intervention
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-04-23 |
| Est. Completion | 2026-04-01 |
| Phase | NA |
What the registry record for NCT04310826 still lists
NCT04310826 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 3,243-participant average among 35 other Ovarian Carcinoma trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Ovarian Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Media Intervention is the first listed.
NCT04310826 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04310826 about?
NCT04310826 is a clinical study titled "Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy". This trial studies how well a diet high in magnesium works in preventing low blood magnesium levels (hypomagnesemia) in patients with ovarian cancer receiving carboplatin chemotherapy. Hypomagnesemia is a common side effect of carboplatin-containing chemotherapy. A magnesium rich diet may increase t...
What is the current status of trial NCT04310826?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 26 participants. The study started on 2019-04-23. Estimated completion is 2026-04-01.
What conditions does trial NCT04310826 study?
This clinical trial studies the following conditions: Ovarian Carcinoma.
What interventions are being tested in trial NCT04310826?
The interventions under investigation include: Media Intervention (OTHER), Dietary Intervention (DIETARY_SUPPLEMENT), Telephone-Based Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT04310826?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04310826 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04310826's enrollment target sits among peer trials
26 30th of 35 higher than 6 of 35 other Ovarian Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
RECRUITING · NA
-
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
RECRUITING · NA
-
Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
RECRUITING · NA
-
Access to Genetic Testing in Underserved Patients With Cancer
RECRUITING · NA
-
The Vanguard Study: Testing a New Way to Screen for Cancer
RECRUITING · NA
-
Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI